Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2009

01-07-2009 | Review

The hedgehog pathway as a therapeutic target for treatment of breast cancer

Authors: M. F. Barginear, M. Leung, D. R. Budman

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Login to get access

Abstract

The Hedgehog (Hh) signaling pathway plays a key role in a variety of processes, such as embryogenesis and maintenance of adult tissue homeostasis. It is also becoming increasingly clear that this pathway can have a crucial role in tumorigenesis. Most recently, the Hh signaling pathway has been implicated in the development and maintenance of breast cancer. Here we review Hh signaling, advances in small molecule and antibody-based inhibitors targeting the Hh pathway, and dysregulation of the Hh signaling pathway in breast cancer.
Literature
1.
go back to reference Ramalho-Santos M, Melton DA, McMahon AP (2000) Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 127(12):2763–2772PubMed Ramalho-Santos M, Melton DA, McMahon AP (2000) Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 127(12):2763–2772PubMed
5.
7.
go back to reference Chang DT et al (1994) Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development 120(11):3339–3353PubMed Chang DT et al (1994) Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development 120(11):3339–3353PubMed
11.
go back to reference Hutchin ME et al (2005) Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19(2):214–223. doi:10.1101/gad.1258705 PubMedCrossRef Hutchin ME et al (2005) Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19(2):214–223. doi:10.​1101/​gad.​1258705 PubMedCrossRef
15.
go back to reference Reifenberger J et al (1998) Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58(9):1798–1803PubMed Reifenberger J et al (1998) Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58(9):1798–1803PubMed
18.
19.
go back to reference Unden AB et al (1997) Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res 57(12):2336–2340PubMed Unden AB et al (1997) Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res 57(12):2336–2340PubMed
22.
go back to reference Daling JR et al (2002) The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 11(3):235–241PubMed Daling JR et al (2002) The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 11(3):235–241PubMed
23.
go back to reference Park CH, Bergsagel DE, McCulloch EA (1971) Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46(2):411–422PubMed Park CH, Bergsagel DE, McCulloch EA (1971) Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46(2):411–422PubMed
32.
go back to reference Lewis MT et al (1999) Defects in mouse mammary gland development caused by conditional haploinsufficiency of patched-1. Development 126(22):5181–5193PubMed Lewis MT et al (1999) Defects in mouse mammary gland development caused by conditional haploinsufficiency of patched-1. Development 126(22):5181–5193PubMed
33.
go back to reference Edwards PA (1998) Control of the three-dimensional growth pattern of mammary epithelium: role of genes of the Wnt and erbB families studied using reconstituted epithelium. Biochem Soc Symp 63:21–34PubMed Edwards PA (1998) Control of the three-dimensional growth pattern of mammary epithelium: role of genes of the Wnt and erbB families studied using reconstituted epithelium. Biochem Soc Symp 63:21–34PubMed
34.
go back to reference Moraes RC et al (2007) Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 134(6):1231–1242. doi:10.1242/dev.02797 PubMedCrossRef Moraes RC et al (2007) Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 134(6):1231–1242. doi:10.​1242/​dev.​02797 PubMedCrossRef
35.
go back to reference Xie J et al (1997) Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57(12):2369–2372PubMed Xie J et al (1997) Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57(12):2369–2372PubMed
36.
go back to reference Chang-Claude J et al (2003) The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer 103(6):779–783. doi:10.1002/ijc.10889 PubMedCrossRef Chang-Claude J et al (2003) The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer 103(6):779–783. doi:10.​1002/​ijc.​10889 PubMedCrossRef
38.
go back to reference Radhakrishna U et al (1999) The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations. Am J Hum Genet 65(3):645–655. doi:10.1086/302557 PubMedCrossRef Radhakrishna U et al (1999) The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations. Am J Hum Genet 65(3):645–655. doi:10.​1086/​302557 PubMedCrossRef
40.
go back to reference Mukherjee S et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5(6):674–683PubMedCrossRef Mukherjee S et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5(6):674–683PubMedCrossRef
42.
go back to reference Russo J, Russo IH (1987) Biological and molecular bases of mammary carcinogenesis. Lab Invest 57(2):112–137PubMed Russo J, Russo IH (1987) Biological and molecular bases of mammary carcinogenesis. Lab Invest 57(2):112–137PubMed
46.
go back to reference Berx G, Nollet F, van Roy F (1998) Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun 6(2–3):171–184PubMedCrossRef Berx G, Nollet F, van Roy F (1998) Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun 6(2–3):171–184PubMedCrossRef
48.
go back to reference Dahmane N et al (2001) The sonic hedgehog-gli pathway regulates dorsal brain growth and tumorigenesis. Development 128(24):5201–5212PubMed Dahmane N et al (2001) The sonic hedgehog-gli pathway regulates dorsal brain growth and tumorigenesis. Development 128(24):5201–5212PubMed
56.
go back to reference Kameda C, Tanaka H, Yamasaki A et al (2009) The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res 29(3):871–879PubMed Kameda C, Tanaka H, Yamasaki A et al (2009) The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res 29(3):871–879PubMed
57.
go back to reference LoRusso PRCM, Borad M, Vernillet L, Darbonne W, Mackey H, DiMartino J, De Sauvage F, Low J, Von Hoff D (2008) A first-in-human, first-in-class, phase (ph) I study of systemic hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. J Clin Oncol 26(No 15S):3516 (May 20 Supplement) LoRusso PRCM, Borad M, Vernillet L, Darbonne W, Mackey H, DiMartino J, De Sauvage F, Low J, Von Hoff D (2008) A first-in-human, first-in-class, phase (ph) I study of systemic hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. J Clin Oncol 26(No 15S):3516 (May 20 Supplement)
58.
go back to reference Tremblay MR, Lescarbeau A, Grogran MJ, Tan E, Lin G Behnke ML, Austad BC, Yu LC, Trudeau M Grenier L, Lo P, Nair SJ, Hagel K, White K, Manna J, Alvarez-Diez T, Hoyt J, Sydor JR, Pink M, MacDougall J, Campbell MJ, McGovern K, Read MA, Palombella VJ, Adams J, Castro AC (2009) Discovery of IPI-926, a semi-synthetic clinical candidate that targets the hedgehog pathway. American Chemical Society Meeting. Presented at American Association for Cancer Research, 2009 Tremblay MR, Lescarbeau A, Grogran MJ, Tan E, Lin G Behnke ML, Austad BC, Yu LC, Trudeau M Grenier L, Lo P, Nair SJ, Hagel K, White K, Manna J, Alvarez-Diez T, Hoyt J, Sydor JR, Pink M, MacDougall J, Campbell MJ, McGovern K, Read MA, Palombella VJ, Adams J, Castro AC (2009) Discovery of IPI-926, a semi-synthetic clinical candidate that targets the hedgehog pathway. American Chemical Society Meeting. Presented at American Association for Cancer Research, 2009
59.
go back to reference Villavicencia E, Khanna P, Ditzler S, Pullar B, Hansen S, Read M, Faia K, Hatton B, Knoblaugh S, Randolph-Habecker J, LeBlanc M, Shaw D, Friedman S, McGovern K, Olson J (2009) Activity of the Hh pathway inhibitor IPI-926 in a mouse model of medulloblastoma. American Association for Cancer Research. Presented at American Association for Cancer Research, 2009 Villavicencia E, Khanna P, Ditzler S, Pullar B, Hansen S, Read M, Faia K, Hatton B, Knoblaugh S, Randolph-Habecker J, LeBlanc M, Shaw D, Friedman S, McGovern K, Olson J (2009) Activity of the Hh pathway inhibitor IPI-926 in a mouse model of medulloblastoma. American Association for Cancer Research. Presented at American Association for Cancer Research, 2009
60.
go back to reference Peacock C, Martelotto LG, Travaglione V, McGovern K, Read M, Berman DM, Matsui W, Watkins DN (2009) Visualization of smoothened activation supports an essential role for hedgehog signaling in the regulation of self-renewal in small cell lung cancer. American Association for Cancer Research. Presented at American Association for Cancer Research, 2009 Peacock C, Martelotto LG, Travaglione V, McGovern K, Read M, Berman DM, Matsui W, Watkins DN (2009) Visualization of smoothened activation supports an essential role for hedgehog signaling in the regulation of self-renewal in small cell lung cancer. American Association for Cancer Research. Presented at American Association for Cancer Research, 2009
61.
62.
go back to reference Parga JA et al (2008) Different effects of anti-sonic hedgehog antibodies and the hedgehog pathway inhibitor cyclopamine on generation of dopaminergic neurons from neurospheres of mesencephalic precursors. Dev Dyn 237(4):909–917. doi:10.1002/dvdy.21481 PubMedCrossRef Parga JA et al (2008) Different effects of anti-sonic hedgehog antibodies and the hedgehog pathway inhibitor cyclopamine on generation of dopaminergic neurons from neurospheres of mesencephalic precursors. Dev Dyn 237(4):909–917. doi:10.​1002/​dvdy.​21481 PubMedCrossRef
73.
79.
go back to reference Growdon WM, McCann CR, Curley M, Friel AM, Mandley E, Ferguson J (2009) Hedgehog pathway inhibitor cyclopamine suppresses Gli1 expression and inhibits serous ovarian cancer xenograft growth. Society of gynecologic oncologists’ annual meeting on women’s cancer Growdon WM, McCann CR, Curley M, Friel AM, Mandley E, Ferguson J (2009) Hedgehog pathway inhibitor cyclopamine suppresses Gli1 expression and inhibits serous ovarian cancer xenograft growth. Society of gynecologic oncologists’ annual meeting on women’s cancer
Metadata
Title
The hedgehog pathway as a therapeutic target for treatment of breast cancer
Authors
M. F. Barginear
M. Leung
D. R. Budman
Publication date
01-07-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0423-0

Other articles of this Issue 2/2009

Breast Cancer Research and Treatment 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine